期刊文献+

miR-455慢病毒表达载体的构建与鉴定 被引量:3

Construction and Function Identification of Recombinant Lentivirus Vector Expressing has-miR-455
下载PDF
导出
摘要 目的:构建人源microRNA-455(miR-455)慢病毒载体,并鉴定成熟has-miR-455在细胞内的表达水平。方法:提取SiHa细胞中的人基因组DNA,设计并合成人miR-455的上下游引物,PCR扩增目的基因,将其中表达miR-455的结构经酶切后插入慢病毒转移质粒pWPT-GFP,构建成pWPT-GFP-pri-miR-455,在293T细胞中与pMD2G、pSPAX2包装产生慢病毒,并用含慢病毒的上清感染SiHa细胞。结果:测序结果证明插入质粒载体中的miR-455前体序列完全正确,慢病毒载体构建成功并获得相应的慢病毒;重组慢病毒质粒pWPT-GFP-pri-miR-455感染SiHa细胞后上调miR-455的表达近40倍。结论:构建了miR-455的慢病毒载体,并能在293T细胞中表达,产生的慢病毒能成功感染SiHa细胞。为进一步研究miR-455的功能,以及利用慢病毒进行基因治疗奠定了基础。 Objective: To construct a lentivirus vector expressing microRNA-455(miR-455) and transfect the vector into SiHa cell line. Methods: Human miR-455 gene with its promoter was amplified by PCR from human SiHa cells genomic DNA. We constructed a lentivirus vector pWPT-GFP containing pri-miR-455 transcript. After having been conformed, the pWPT-GFP-pri-miR-455 plasmid was co-transfected with framework plasmid pMD2G, pSPAX2 into 293T cells to obtain the miR-455 lentivirus vector. After the lentivirus expression vector pWPT- GFP-pri-miR-455 was transduced into SiHa cells, the transduction efficiency was determined by real-time PCR. Results: The inserted pre-miR-455 sequence of plasmid vectors was absolutely correct confirmed by sequencing re- suits, miR-455 was notable up-regulation after transfecting SiHa cells with recombinant lentivirus vector pWPT- GFP-pri-miR-455. Conclusion: The recombinant lentivirus vector for miR-455 was successfully constructed which expressed in 293T cells, and then infected with SiHa cells. The study may lay a foundation on further researehing the function of miR-455 and gene therapy by lentivirus .
出处 《生物技术通讯》 CAS 2013年第1期49-52,共4页 Letters in Biotechnology
基金 国家自然科学基金(81101486)
关键词 miR-455 慢病毒表达载体 SIHA细胞 miR-455 lentivirus expression plasmid SiHa cells
  • 相关文献

参考文献9

  • 1Bartel D P. MicroRNAs:genomics,biogenesis,mechanism,and function[J].{H}CELL,2004,(02):281-297.
  • 2Ambros V. The functions of animal microRNAs[J].{H}NATURE,2004,(7006):350-355.doi:10.1038/nature02871.
  • 3Mendell J T. MicroRNAs:critical regulators of development,cellular physiology and malignancy[J].{H}CELL CYCLE,2005,(09):1179-1184.
  • 4Bushati N,Cohen S M. microRNA functions[J].{H}Annual Review of Cell and Developmental Biology,2007.175-205.
  • 5Ambros V. MicroRNA pathways in flies and worms:growth,death,fat,stress,and timing[J].{H}CELL,2003,(06):673-676.
  • 6Naldini L,Blomer U,Gallay P. In vivo gene delivery and sta-ble transduction of nondividing cells by a lentiviral vector[J].{H}SCIENCE,1996,(5259):263-267.
  • 7Williams A E. Functional aspects of animal microRNAs[J].{H}Cellular and Molecular Life Sciences,2008,(04):545-562.
  • 8Lewis B P,Burge C B,Bartel D P. Conserved seed pairing,often flanked by adenosines,indicates that thousands of hu-man genes are microRNA targets[J].{H}CELL,2005,(01):15-20.
  • 9Chitwood D H,Timmermans M C. Target mimics modulate miRNAs[J].{H}Nature genetics,2007,(08):935-936.

同被引文献35

  • 1Cao Y, E G, Wang E, et al. VEGF exerts an angiogenesis in de- pendent function in cancer cells to promote their malignant progres- sion[J]. Cancer Res,2012,72(16) :3912 -3918.
  • 2Ding M, Fu X, Tan H, et al. The effect of vascular endothelial growth factor C expression in tumor associated macrophages on lymphangiogenesis and lymphatic metastasis in breast cancer[ J]. Mol Med Report,2012,6(5):1023- 1029.
  • 3Benedet JL, Bender H, Jones H, et al. FIGO staging classifications and clinical practice guidelines in the management of :necologic cancers. FIGO Committee On Gynecologic Oncalogy [ J ]. Int J Gyaecol Obstet,2000,70(2) :209 -262.
  • 4Chen C, Ridzon DA, Broomer A J, et al. Real - time quantification of microRNAs by stem - loop RT - PCR [ J ]. Nucleic Acids Res, 2005,33 (20) :e179.
  • 5Stamatopoulos B, Meulenmn N, Haibe Kains B, et al. microRNA - 29c and microRNA - 223 down - regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratifi- cation [ J ]. Blood, 2009,113 ( 21 ) :5237 - 5245.
  • 6Molhoek KR, (,riesemann tl, Shu J. ltuman melanoma cytolysis by combined inhibition of" mammalian target of rapamycin anti vascular endothelial growth factor/vascular endothelial growth factor- 2 [ J ]. Cancer Res,2008,68 (110) :4392 - 4397.
  • 7lorio MV,Croce CM. MicroRNA dysregulation in cancer: diagnos- tics ,monitoring and therapeutics. A comprehensive review[ J]. EM- BO Mol Med,2012,4(3) :143 -159.
  • 8Iorio MV, Croce CM. Causes and consequences of MicroRNA dys- regulation [ J ]. Cancer J,2012,18 ( 3 ) :215 - 222.
  • 9Sand M, Skrygan M, Sand D, et al. Expression of microRNAs in basal cell carcinoma[ J]. Br J Dermatol,2012 ,4 :27.
  • 10Roybal JD,Zang Y, Ahn YH, et al. miR -200 inhibits lung ade- nocarcinoma ceil invasion and metastasis by targeting Fltl/VEG- FR1 Fltl/VEGFR1 [J]. Mol Cancer Res,2011,9( 1 ) :25 -35.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部